Therefore, the upregulation of alternative proangiogenic signaling pathways similar in function of VEGF/R signaling is a potential mechanism of resistance e.g. PlGF was significantly upregulated during ramucirumab (VEGFR2 monoclonal antibody) therapy in HCC patients [30]. The gene discussed is PGF; the disease is hepatocellular carcinoma.